FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug

The U.S. Food and Drug Administration declined to approve Merck (MRK.N) and Japan-based Daiichi Sankyo's (4568.T),  lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".